Bay­er en­lists Jür­gen Eck­hardt to leap in­to an ad­di­tion­al role; Mi­rati tops list of mul­ti­ple CFO ex­its

→ Jür­gen Eck­hardt’s re­spon­si­bil­i­ties at Bay­er will ex­pand on Sept. 1, as he be­comes the head of busi­ness de­vel­op­ment & li­cens­ing/open in­no­va­tion for the Ger­man con­glom­er­ate’s phar­ma­ceu­ti­cals di­vi­sion. Eck­hardt will be pulling dou­ble du­ty as he con­tin­ues to run Leaps by Bay­er, the ven­ture arm that has backed such biotechs as Affi­ni-T Ther­a­peu­tics, Bound­less Bio and Tim Lu’s Sen­ti Bio. Friede­mann Janus stepped up to the plate in an in­ter­im ca­pac­i­ty and had ex­pressed his in­ter­est in be­ing the per­ma­nent suc­ces­sor to Mar­i­anne De Backer, who’s in her first year as CEO of Vir Biotech­nol­o­gy. “One of the things that the man­age­ment board is re­al­ly fo­cused on is how do we rad­i­cal­ly ac­cel­er­ate every­thing at Bay­er,” new CEO Bill An­der­son said in his maid­en earn­ings call. “Our bench­mark isn’t oth­er large com­pa­nies — our bench­mark is a sole pro­pri­etor, a start­up.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER